Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 4525 entries
Sorted by: Best Match Show Resources per page
Developing interventions for cancer-related cognitive dysfunction in childhood cancer survivors

Stem career interventions

[No authors listed]
GSID: nMIDJegM7k4J
SM Castellino, NJ Ullrich, MJ Whelen… - Journal of the National …, 2014 - academic.oup.com

Survivors of childhood cancer frequently experience cancer-related cognitive dysfunction, commonly months to years after treatment for pediatric brain tumors, acute lymphoblastic leukemia (ALL), or tumors involving the head and neck. Risk factors for cancer-related cognitive dysfunction include young age...

Cite
CASTELLINO, Sharon M., et al. Developing interventions for cancer-related cognitive dysfunction in childhood cancer survivors. Journal of the National Cancer Institute, 2014, vol. 106, no 8, p. dju186.
Castellino, S. M., Ullrich, N. J., Whelen, M. J., & Lange, B. J. (2014). Developing interventions for cancer-related cognitive dysfunction in childhood cancer survivors. Journal of the National Cancer Institute, 106(8), dju186.
Copy Download .nbib Format: MLA
Composite polylactic-methacrylic Acid copolymer nanoparticles for the delivery of methotrexate.

Journal of drug delivery

Sibeko B, Choonara YE, du Toit LC, Modi G, Naidoo D, Khan RA, Kumar P, Ndesendo VM, Iyuke SE, Pillay V.
PMID: 22919501
J Drug Deliv. 2012;2012:579629. doi: 10.1155/2012/579629. Epub 2012 Jul 05.

The purpose of this study was to develop poly(lactic acid)-methacrylic acid copolymeric nanoparticles with the potential to serve as nanocarrier systems for methotrexate (MTX) used in the chemotherapy of primary central nervous system lymphoma (PCNSL). Nanoparticles were prepared by...

Cite
Sibeko B, Choonara YE, du Toit LC, et al. Composite polylactic-methacrylic Acid copolymer nanoparticles for the delivery of methotrexate. J Drug Deliv. 2012;2012:579629doi: 10.1155/2012/579629.
Sibeko, B., Choonara, Y. E., du Toit, L. C., Modi, G., Naidoo, D., Khan, R. A., Kumar, P., Ndesendo, V. M., Iyuke, S. E., & Pillay, V. (2012). Composite polylactic-methacrylic Acid copolymer nanoparticles for the delivery of methotrexate. Journal of drug delivery, 2012579629. https://doi.org/10.1155/2012/579629
Sibeko, Bongani, et al. "Composite polylactic-methacrylic Acid copolymer nanoparticles for the delivery of methotrexate." Journal of drug delivery vol. 2012 (2012): 579629. doi: https://doi.org/10.1155/2012/579629
Sibeko B, Choonara YE, du Toit LC, Modi G, Naidoo D, Khan RA, Kumar P, Ndesendo VM, Iyuke SE, Pillay V. Composite polylactic-methacrylic Acid copolymer nanoparticles for the delivery of methotrexate. J Drug Deliv. 2012;2012:579629. doi: 10.1155/2012/579629. Epub 2012 Jul 05. PMID: 22919501; PMCID: PMC3418700.
Copy Download .nbib Format: NLM
Changes of fundus autofluorescence and spectral-domain optical coherence tomographic findings after treatment of primary intraocular lymphoma.

Journal of ophthalmic inflammation and infection

Egawa M, Mitamura Y, Hayashi Y, Semba K, Naito T.
PMID: 24559259
J Ophthalmic Inflamm Infect. 2014 Feb 22;4(1):7. doi: 10.1186/1869-5760-4-7.

BACKGROUND: We report the fundus autofluorescence (FAF), spectral-domain optical coherence tomographic (SD-OCT), microperimetric, and multifocal electroretinographic (mfERG) findings before, during, and after successful treatment of a primary intraocular lymphoma (PIOL).FINDINGS: A 57-year-old man had biopsy-proven PIOL in his left...

Cite
Egawa M, Mitamura Y, Hayashi Y, et al. Changes of fundus autofluorescence and spectral-domain optical coherence tomographic findings after treatment of primary intraocular lymphoma. J Ophthalmic Inflamm Infect. 2014;4(1):7doi: 10.1186/1869-5760-4-7.
Egawa, M., Mitamura, Y., Hayashi, Y., Semba, K., & Naito, T. (2014). Changes of fundus autofluorescence and spectral-domain optical coherence tomographic findings after treatment of primary intraocular lymphoma. Journal of ophthalmic inflammation and infection, 4(1), 7. https://doi.org/10.1186/1869-5760-4-7
Egawa, Mariko, et al. "Changes of fundus autofluorescence and spectral-domain optical coherence tomographic findings after treatment of primary intraocular lymphoma." Journal of ophthalmic inflammation and infection vol. 4,1 (2014): 7. doi: https://doi.org/10.1186/1869-5760-4-7
Egawa M, Mitamura Y, Hayashi Y, Semba K, Naito T. Changes of fundus autofluorescence and spectral-domain optical coherence tomographic findings after treatment of primary intraocular lymphoma. J Ophthalmic Inflamm Infect. 2014 Feb 22;4(1):7. doi: 10.1186/1869-5760-4-7. PMID: 24559259; PMCID: PMC3944943.
Copy Download .nbib Format: NLM
Does the p38 MAP kinase inhibitor pamapimod have potential for the treatment of rheumatoid arthritis?.

Expert opinion on pharmacotherapy

Doggrell SA, Christensen AM.
PMID: 20666701
Expert Opin Pharmacother. 2010 Oct;11(14):2437-42. doi: 10.1517/14656566.2010.507631.

Methotrexate alone or in combination with other agents is the standard treatment for moderate-to-severe rheumatoid arthritis. As biological agents are expensive, they are not usually used until methotrexate has failed to give a good response. Thus, there is scope...

Cite
Doggrell SA, Christensen AM. Does the p38 MAP kinase inhibitor pamapimod have potential for the treatment of rheumatoid arthritis?. Expert Opin Pharmacother. 2010;11(14):2437-42doi: 10.1517/14656566.2010.507631.
Doggrell, S. A., & Christensen, A. M. (2010). Does the p38 MAP kinase inhibitor pamapimod have potential for the treatment of rheumatoid arthritis?. Expert opinion on pharmacotherapy, 11(14), 2437-42. https://doi.org/10.1517/14656566.2010.507631
Doggrell, Sheila A, and Christensen, Anne-Marie. "Does the p38 MAP kinase inhibitor pamapimod have potential for the treatment of rheumatoid arthritis?." Expert opinion on pharmacotherapy vol. 11,14 (2010): 2437-42. doi: https://doi.org/10.1517/14656566.2010.507631
Doggrell SA, Christensen AM. Does the p38 MAP kinase inhibitor pamapimod have potential for the treatment of rheumatoid arthritis?. Expert Opin Pharmacother. 2010 Oct;11(14):2437-42. doi: 10.1517/14656566.2010.507631. PMID: 20666701.
Copy Download .nbib Format: NLM
Expression levels of multidrug resistance-associated protein 4 (MRP4) in human leukemia and lymphoma cell lines, and the inhibitory effects of the MRP-specific inhibitor MK-571 on methotrexate distribution in rats.

Experimental and therapeutic medicine

Takeuchi K, Shibata M, Kashiyama E, Umehara K.
PMID: 23181130
Exp Ther Med. 2012 Sep;4(3):524-532. doi: 10.3892/etm.2012.627. Epub 2012 Jun 29.

In the development of anti-blood cancer drugs, the chronic myelocytic leukemia (KU812), acute myelocytic leukemia (KG-1) and lymphoma (U937) cell lines are commonly used in preclinical pharmacology studies as human cancer xenograft models in mice. In the present study,...

Cite
Takeuchi K, Shibata M, Kashiyama E, et al. Expression levels of multidrug resistance-associated protein 4 (MRP4) in human leukemia and lymphoma cell lines, and the inhibitory effects of the MRP-specific inhibitor MK-571 on methotrexate distribution in rats. Exp Ther Med. 2012;4(3):524-532doi: 10.3892/etm.2012.627.
Takeuchi, K., Shibata, M., Kashiyama, E., & Umehara, K. (2012). Expression levels of multidrug resistance-associated protein 4 (MRP4) in human leukemia and lymphoma cell lines, and the inhibitory effects of the MRP-specific inhibitor MK-571 on methotrexate distribution in rats. Experimental and therapeutic medicine, 4(3), 524-532. https://doi.org/10.3892/etm.2012.627
Takeuchi, Kenji, et al. "Expression levels of multidrug resistance-associated protein 4 (MRP4) in human leukemia and lymphoma cell lines, and the inhibitory effects of the MRP-specific inhibitor MK-571 on methotrexate distribution in rats." Experimental and therapeutic medicine vol. 4,3 (2012): 524-532. doi: https://doi.org/10.3892/etm.2012.627
Takeuchi K, Shibata M, Kashiyama E, Umehara K. Expression levels of multidrug resistance-associated protein 4 (MRP4) in human leukemia and lymphoma cell lines, and the inhibitory effects of the MRP-specific inhibitor MK-571 on methotrexate distribution in rats. Exp Ther Med. 2012 Sep;4(3):524-532. doi: 10.3892/etm.2012.627. Epub 2012 Jun 29. PMID: 23181130; PMCID: PMC3503844.
Copy Download .nbib Format: NLM
Lipid-Coated Nanoscale Coordination Polymers for Targeted Delivery of Antifolates to Cancer Cells.

Chemical science

Huxford RC, Dekrafft KE, Boyle WS, Liu D, Lin W.
PMID: 24288587
Chem Sci. 2012;3(1). doi: 10.1039/C1SC00499A.

Nanoscale coordination polymers (NCPs) have been demonstrated as an interesting platform for drug delivery, as they possess many advantages over small-molecule chemotherapeutics, such as high payloads, lower systemic toxicity, tunability, and enhanced tumor uptake. Existing formulations for the delivery...

Cite
Huxford RC, Dekrafft KE, Boyle WS, et al. Lipid-Coated Nanoscale Coordination Polymers for Targeted Delivery of Antifolates to Cancer Cells. Chem Sci. 2012;3(1)doi: 10.1039/C1SC00499A.
Huxford, R. C., Dekrafft, K. E., Boyle, W. S., Liu, D., & Lin, W. (2012). Lipid-Coated Nanoscale Coordination Polymers for Targeted Delivery of Antifolates to Cancer Cells. Chemical science, 3(1), . https://doi.org/10.1039/C1SC00499A
Huxford, Rachel C, et al. "Lipid-Coated Nanoscale Coordination Polymers for Targeted Delivery of Antifolates to Cancer Cells." Chemical science vol. 3,1 (2012). doi: https://doi.org/10.1039/C1SC00499A
Huxford RC, Dekrafft KE, Boyle WS, Liu D, Lin W. Lipid-Coated Nanoscale Coordination Polymers for Targeted Delivery of Antifolates to Cancer Cells. Chem Sci. 2012;3(1). doi: 10.1039/C1SC00499A. PMID: 24288587; PMCID: PMC3840543.
Copy Download .nbib Format: NLM
Methotrexate as a Corticosteroid-Sparing Agent for Thyroid Eye Disease.

Journal of clinical & experimental ophthalmology

Rivera-Grana E, Lin P, Suhler EB, Rosenbaum JT.
PMID: 26807304
J Clin Exp Ophthalmol. 2015 Apr;6(2). doi: 10.4172/2155-9570.1000422. Epub 2015 Apr 27.

OBJECTIVE: Thyroid eye disease (TED) is generally treated with oral corticosteroid therapy. A steroid sparing drug could be a useful adjunct. We reviewed our experience with methotrexate as a corticosteroid sparing agent to treat TED.METHODS: Retrospective chart review from...

Cite
Rivera-Grana E, Lin P, Suhler EB, et al. Methotrexate as a Corticosteroid-Sparing Agent for Thyroid Eye Disease. J Clin Exp Ophthalmol. 2015;6(2)doi: 10.4172/2155-9570.1000422.
Rivera-Grana, E., Lin, P., Suhler, E. B., & Rosenbaum, J. T. (2015). Methotrexate as a Corticosteroid-Sparing Agent for Thyroid Eye Disease. Journal of clinical & experimental ophthalmology, 6(2), . https://doi.org/10.4172/2155-9570.1000422
Rivera-Grana, Erick, et al. "Methotrexate as a Corticosteroid-Sparing Agent for Thyroid Eye Disease." Journal of clinical & experimental ophthalmology vol. 6,2 (2015). doi: https://doi.org/10.4172/2155-9570.1000422
Rivera-Grana E, Lin P, Suhler EB, Rosenbaum JT. Methotrexate as a Corticosteroid-Sparing Agent for Thyroid Eye Disease. J Clin Exp Ophthalmol. 2015 Apr;6(2). doi: 10.4172/2155-9570.1000422. Epub 2015 Apr 27. PMID: 26807304; PMCID: PMC4718577.
Copy Download .nbib Format: NLM
Magnetic Resonance Elastography for Liver Fibrosis in Methotrexate Treatment.

Open journal of rheumatology and autoimmune diseases

Hoganson DD, Chen J, Ehman RL, Talwalkar JA, Michet CJ, Yin M, Crowson CS, Matteson EL.
PMID: 26361561
Open J Rheumatol Autoimmune Dis. 2012 May;2(2):6-13. doi: 10.4236/ojra.2012.22003.

INTRODUCTION: Hepatic magnetic resonance elastography (MRE) allows for noninvasive assessment of liver fibrosis. The purpose of this study was to evaluate the usefulness of MRE in detecting and quantifying liver fibrosis in patients with rheumatoid arthritis (RA) who have...

Cite
Hoganson DD, Chen J, Ehman RL, et al. Magnetic Resonance Elastography for Liver Fibrosis in Methotrexate Treatment. Open J Rheumatol Autoimmune Dis. 2012;2(2):6-13doi: 10.4236/ojra.2012.22003.
Hoganson, D. D., Chen, J., Ehman, R. L., Talwalkar, J. A., Michet, C. J., Yin, M., Crowson, C. S., & Matteson, E. L. (2012). Magnetic Resonance Elastography for Liver Fibrosis in Methotrexate Treatment. Open journal of rheumatology and autoimmune diseases, 2(2), 6-13. https://doi.org/10.4236/ojra.2012.22003
Hoganson, Deana D, et al. "Magnetic Resonance Elastography for Liver Fibrosis in Methotrexate Treatment." Open journal of rheumatology and autoimmune diseases vol. 2,2 (2012): 6-13. doi: https://doi.org/10.4236/ojra.2012.22003
Hoganson DD, Chen J, Ehman RL, Talwalkar JA, Michet CJ, Yin M, Crowson CS, Matteson EL. Magnetic Resonance Elastography for Liver Fibrosis in Methotrexate Treatment. Open J Rheumatol Autoimmune Dis. 2012 May;2(2):6-13. doi: 10.4236/ojra.2012.22003. PMID: 26361561; PMCID: PMC4562680.
Copy Download .nbib Format: NLM
The Potential Use of Methotrexate in the Treatment of Cutaneous Leishmaniasis: In Vitro Assays against Sensitive and Meglumine Antimoniate-resistant Strains of .

Iranian journal of parasitology

Mahmoudvand H, Kheirandish F, Mirbadie SR, Kayedi MH, Rezaei Riabi T, Ghasemi AA, Bamorovat M, Sharifi I.
PMID: 28979343
Iran J Parasitol. 2017 Jul-Sep;12(3):339-347.

BACKGROUND: The present study aimed to evaluate the effect of methotrexate (MTX) alone and in combination with meglumine antimoniate (MA, Glucantime) against sensitive and MA-resistant METHODS: The present study was carried out in 2014 in Leishmaniasis Research Center at...

Cite
Mahmoudvand H, Kheirandish F, Mirbadie SR, et al. The Potential Use of Methotrexate in the Treatment of Cutaneous Leishmaniasis: In Vitro Assays against Sensitive and Meglumine Antimoniate-resistant Strains of . Iran J Parasitol. 2017;12(3):339-347
Mahmoudvand, H., Kheirandish, F., Mirbadie, S. R., Kayedi, M. H., Rezaei Riabi, T., Ghasemi, A. A., Bamorovat, M., & Sharifi, I. (2017). The Potential Use of Methotrexate in the Treatment of Cutaneous Leishmaniasis: In Vitro Assays against Sensitive and Meglumine Antimoniate-resistant Strains of . Iranian journal of parasitology, 12(3), 339-347.
Mahmoudvand, Hossein, et al. "The Potential Use of Methotrexate in the Treatment of Cutaneous Leishmaniasis: In Vitro Assays against Sensitive and Meglumine Antimoniate-resistant Strains of ." Iranian journal of parasitology vol. 12,3 (2017): 339-347.
Mahmoudvand H, Kheirandish F, Mirbadie SR, Kayedi MH, Rezaei Riabi T, Ghasemi AA, Bamorovat M, Sharifi I. The Potential Use of Methotrexate in the Treatment of Cutaneous Leishmaniasis: In Vitro Assays against Sensitive and Meglumine Antimoniate-resistant Strains of . Iran J Parasitol. 2017 Jul-Sep;12(3):339-347. PMID: 28979343; PMCID: PMC5623913.
Copy Download .nbib Format: NLM
MRI in Chemotherapy induced Leukoencephalopathy: Report of Two Cases and Radiologist's Perspective.

Journal of clinical and diagnostic research : JCDR

Sindhwani G, Arora M, Thakker VD, Jain A.
PMID: 28893007
J Clin Diagn Res. 2017 Jul;11(7):TD08-TD09. doi: 10.7860/JCDR/2017/29164.10248. Epub 2017 Jul 01.

Leukoencephalopathy is a progressive white matter disease primarily caused due to myelin damage by a variety of factors. Chemotherapy for oncological treatment is an uncommon but important cause of potentially reversible leukoencephalopathy. In current radiological setting, conventional and diffusion...

Cite
Sindhwani G, Arora M, Thakker VD, et al. MRI in Chemotherapy induced Leukoencephalopathy: Report of Two Cases and Radiologist's Perspective. J Clin Diagn Res. 2017;11(7):TD08-TD09doi: 10.7860/JCDR/2017/29164.10248.
Sindhwani, G., Arora, M., Thakker, V. D., & Jain, A. (2017). MRI in Chemotherapy induced Leukoencephalopathy: Report of Two Cases and Radiologist's Perspective. Journal of clinical and diagnostic research : JCDR, 11(7), TD08-TD09. https://doi.org/10.7860/JCDR/2017/29164.10248
Sindhwani, Geetika, et al. "MRI in Chemotherapy induced Leukoencephalopathy: Report of Two Cases and Radiologist's Perspective." Journal of clinical and diagnostic research : JCDR vol. 11,7 (2017): TD08-TD09. doi: https://doi.org/10.7860/JCDR/2017/29164.10248
Sindhwani G, Arora M, Thakker VD, Jain A. MRI in Chemotherapy induced Leukoencephalopathy: Report of Two Cases and Radiologist's Perspective. J Clin Diagn Res. 2017 Jul;11(7):TD08-TD09. doi: 10.7860/JCDR/2017/29164.10248. Epub 2017 Jul 01. PMID: 28893007; PMCID: PMC5583911.
Copy Download .nbib Format: NLM
Atherosclerosis in psoriatic disease: latest evidence and clinical implications.

Therapeutic advances in musculoskeletal disease

Eder L, Gladman DD.
PMID: 26425147
Ther Adv Musculoskelet Dis. 2015 Oct;7(5):187-95. doi: 10.1177/1759720X15591801.

It is widely accepted that atherosclerosis is caused by chronic low-grade inflammation that results from an interaction between immune mechanisms and metabolic abnormalities within the vessel wall. Population-based studies have found an increased cardiovascular risk in patients with psoriasis...

Cite
Eder L, Gladman DD. Atherosclerosis in psoriatic disease: latest evidence and clinical implications. Ther Adv Musculoskelet Dis. 2015;7(5):187-95doi: 10.1177/1759720X15591801.
Eder, L., & Gladman, D. D. (2015). Atherosclerosis in psoriatic disease: latest evidence and clinical implications. Therapeutic advances in musculoskeletal disease, 7(5), 187-95. https://doi.org/10.1177/1759720X15591801
Eder, Lihi, and Gladman, Dafna D. "Atherosclerosis in psoriatic disease: latest evidence and clinical implications." Therapeutic advances in musculoskeletal disease vol. 7,5 (2015): 187-95. doi: https://doi.org/10.1177/1759720X15591801
Eder L, Gladman DD. Atherosclerosis in psoriatic disease: latest evidence and clinical implications. Ther Adv Musculoskelet Dis. 2015 Oct;7(5):187-95. doi: 10.1177/1759720X15591801. PMID: 26425147; PMCID: PMC4572363.
Copy Download .nbib Format: NLM
Efficacy of biological agents administered as monotherapy in rheumatoid arthritis: a Bayesian mixed-treatment comparison analysis.

Therapeutics and clinical risk management

Migliore A, Bizzi E, Egan CG, Bernardi M, Petrella L.
PMID: 26366085
Ther Clin Risk Manag. 2015 Sep 01;11:1325-35. doi: 10.2147/TCRM.S89678. eCollection 2015.

BACKGROUND: Biological agents provide an important therapeutic alternative for rheumatoid arthritis patients refractory to conventional disease-modifying antirheumatic drugs. Few head-to-head comparative trials are available.PURPOSE: The aim of this meta-analysis was to compare the relative efficacy of different biologic agents...

Cite
Migliore A, Bizzi E, Egan CG, et al. Efficacy of biological agents administered as monotherapy in rheumatoid arthritis: a Bayesian mixed-treatment comparison analysis. Ther Clin Risk Manag. 2015;11:1325-35doi: 10.2147/TCRM.S89678.
Migliore, A., Bizzi, E., Egan, C. G., Bernardi, M., & Petrella, L. (2015). Efficacy of biological agents administered as monotherapy in rheumatoid arthritis: a Bayesian mixed-treatment comparison analysis. Therapeutics and clinical risk management, 111325-35. https://doi.org/10.2147/TCRM.S89678
Migliore, Alberto, et al. "Efficacy of biological agents administered as monotherapy in rheumatoid arthritis: a Bayesian mixed-treatment comparison analysis." Therapeutics and clinical risk management vol. 11 (2015): 1325-35. doi: https://doi.org/10.2147/TCRM.S89678
Migliore A, Bizzi E, Egan CG, Bernardi M, Petrella L. Efficacy of biological agents administered as monotherapy in rheumatoid arthritis: a Bayesian mixed-treatment comparison analysis. Ther Clin Risk Manag. 2015 Sep 01;11:1325-35. doi: 10.2147/TCRM.S89678. eCollection 2015. PMID: 26366085; PMCID: PMC4562742.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 4525 entries